AI-based Digital Pathology Market Reach USD 2.11 Bn by 2032

The global AI-based digital pathology market size is expected to be worth USD 1.19 billion in 2025. It can balloon to a valuation of USD 2.11 billion by 2032. The market is anticipated to exhibit a CAGR of 8.5% during the forecast period (2025-2032).  

The breakthroughs in artificial intelligence (AI) driven image analytics, research and development investments, and adoption by hospitals globally can drive the market growth. The focus on efficiency in healthcare workflows, as well as the demand for accurate diagnosis, can further fuel demand over the forecast period.

However, high implementation costs of AI can limit its adoption among smaller institutions and slow down the market growth.

The AI-based digital pathology market is expected to grow due to increasing demand for real-time collaboration between doctors for rare medical cases and improvements in personalized medicines.

Personalized medicine and the surge in rare diseases has triggered the demand for faster diagnostics. The advances in whole slide images (WSI) analysis in digital pathology and the growing use of cloud models for storage and management of WSI can open new market opportunities.

The use of AI tools for morphological assessment of tissue samples is a prime instance likely to drive the AI-based digital pathology market over the forecast period. For instance, Endeavor Health announced the development of a digital pathology platform in collaboration with Google Cloud on April 11, 2025. This partnership can enable collaboration between physicians and encourage patients to participate in improving the healthcare journey.

The adoption of digital pathology systems powered by AI can be attributed to its diagnostic precision and the use of telepathology for remote consultations. The improved ability of AI in the processing and analysis of digital pathology images for detecting abnormalities faster can fuel market growth.

The issues with traditional computational pathology methods, such as support vector machines (SVM) and k-nearest neighbors, like diagnostic accuracy, can drive the demand for computational pathology combined with AI.

Identification of genetic variants with distinct traits and analysis of genomic datasets for faster identification of cancers can drive AI-based digital pathology market growth. On April 18, 2025, Leidos Holdings, Inc. agreed to collaborate the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE) for the next 5 years on the use of AI for the detection of cancer and other abnormalities.

The use of AI and AI tools make a majority of patients uncomfortable. Patients believe that the integration of AI will accelerate healthcare workflows but can forget the accurate diagnosis of patients in its haste. According to a survey in 2023 by the Pew Research Center, U.S., a majority of the patients surveyed are unconvinced of the benefits of AI in improving health outcomes. Nearly 57% of the patients believe the use of AI will worsen the relationship between patients and healthcare providers.

The Future Health Index 2025 report by Koninklijke Philips N.V.  stated gaps in the trust towards AI by patients aged 45 and older and 69% share of clinicians can impede market growth.

However, safeguards to ensure patient safety and regulatory frameworks for the utilization of AI in healthcare settings can open up new opportunities.

Roche Diagnostics expanded its digital pathology open environment by integrating more than 20 AI algorithms on September 09, 2024. The AI tools can assist pathologists in their research and benefit cancer patients.